Using AI to select patients for atrial fibrillation catheter ablation
Artificial Intelligence Guided Patient Selection for Atrial Fibrillation Catheter Ablation: Randomized Clinical Trial (AI-PAFA Trial)
NA · Yonsei University · NCT04997824
This study tests if using artificial intelligence to choose patients for atrial fibrillation catheter ablation can lead to better outcomes compared to the usual methods.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Yonsei University (other) |
| Locations | 1 site (Seoul) |
| Trial ID | NCT04997824 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of artificial intelligence (AI) to improve patient selection for atrial fibrillation catheter ablation (AFCA). It involves a prospective randomization of 1000 patients into two groups: one guided by AI predictions and the other following conventional clinical guidelines. The study aims to evaluate the efficacy of AI in predicting poor responders to AFCA and to track patient outcomes through regular follow-ups. The trial will also assess adverse events and hospitalization rates between the two groups.
Who should consider this trial
Good fit: Ideal candidates include patients with recurrent atrial fibrillation who are eligible for anticoagulant therapy and have a left atrium size of less than 55 mm.
Not a fit: Patients with severe cardiac anomalies, active internal bleeding, or serious comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the recurrence of atrial fibrillation and improve patient outcomes after catheter ablation.
How similar studies have performed: Other studies have shown promise in using AI for patient selection in various medical procedures, indicating potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Left atrium size \< 55 mm 2. AF recurred during the administration of antiarrhythmic drugs or that antiarrhythmic drugs intolerable patients 3. Patients eligible for anticoagulant therapy (to prevent thromboembolic events) Exclusion Criteria: 1. AF associated with severe cardiac anomalies or structural heart disease with hemodynamic influence 2. Patients who have difficulty in CT imaging using a contrast medium 3. Patients with active internal bleeding 4. Inappropriate anticoagulant therapy 5. Serious comorbidities 6. Patients expected to survive less than 1 year 7. People with drug or alcohol addiction 8. Those who cannot read the consent form (illiterate, foreigners, etc.) 9. Patients who are judged unsuitable for participation in clinical research by the judgment of other investigators
Where this trial is running
Seoul
- Severance Hospital, Yonsei University Health System — Seoul, South Korea (RECRUITING)
Study contacts
- Principal investigator: Hui-Nam Pak — Severance Hospital, Yonsei University Health System
- Study coordinator: Hui-Nam Pak
- Email: hnpak@yuhs.ac
- Phone: 82-2-2228-8459
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Atrial Fibrillation